Vyvanse
NDC 59417-104, lisdexamfetamine dimesylate, capsule, from Takeda Pharmaceuticals America, Inc..
- Product NDC
- 59417-104
- Status
- Listed
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Dosage form
- CAPSULE
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application
- NDA021977
- DEA schedule
- CII
curl https://api.healthcare.dev/v1/drugs/ndc/59417-104 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- LISDEXAMFETAMINE DIMESYLATE40 mg/1
Pharmacologic classes
Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 59417-104-10 | 59417010410 | 100 CAPSULE in 1 BOTTLE (59417-104-10) |
Linked data
RxNorm, label and prices
Related lookups
FDA label sections
GET /v1/drugs/labels/704e4378-ca83-445c-8b45-3cfa51c1ecadNADAC price for package 59417010410
GET /v1/drugs/nadac/59417010410
Use it
Look up 59417-104 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/59417-104 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 59417-104. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.